BioCentury
ARTICLE | Company News

OxiGene, Boston Medical Center deal

April 15, 2013 7:00 AM UTC

The center, affiliated with Boston University Medical Center, will collaborate with the company under a sponsored research agreement to study OXGN's Neu-Sensamide and Oxi-104 as chemosensitizers of cordycepin (3'-deoxyadenosin). OXGN has an option to acquire an exclusive worldwide, royalty bearing license to cordycepin. ...